KalVista Pharmaceuticals, Inc.
DE ˙ DB ˙ US4834971032
23,01 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:4XC1 / KalVista Pharmaceuticals, Inc.
InstitutionBnp Paribas Arbitrage, Sa
Latest Disclosed Ownership11,974 shares
Latest Disclosed Value $ 241,037
Bnp Paribas Arbitrage, Sa reports 192.76% increase in ownership of 4XC1 / KalVista Pharmaceuticals, Inc.

On May 12, 2026 - Bnp Paribas Arbitrage, Sa filed a 13F-HR form disclosing ownership of 11,974 shares of KalVista Pharmaceuticals, Inc. (DE:4XC1) valued at $185,597 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 4,090 shares of KalVista Pharmaceuticals, Inc.. This represents a change in shares of 192.76% during the quarter. The current value of the position is $275,522 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F KalVista Pharmaceuticals Equity 483497103 11,974 7,884 192.76 241 265.15 0.0000
2026-02-10 2025-12-31 13F KalVista Pharmaceuticals Equity 483497103 4,090 -3,704 -47.52 66 -29.79 0.0000
2025-11-13 2025-09-30 13F KalVista Pharmaceuticals Equity 483497103 7,794 3,753 92.87 95 108.89 0.0001
2025-08-14 2025-06-30 13F KalVista Pharmaceuticals Equity 483497103 4,041 1,292 47.00 46 45.16 0.0000
2025-05-14 2025-03-31 13F KalVista Pharmaceuticals Equity 483497103 2,749 -3,503 -56.03 32 -40.38 0.0000
2025-02-14 2024-12-31 13F KalVista Pharmaceuticals Equity 483497103 6,252 -37,044 -85.56 53 -89.62 0.0000
2024-11-13 2024-09-30 13F KalVista Pharmaceuticals Equity 483497103 43,296 40,280 1,335.54 501 1,331.43 0.0003
2024-08-13 2024-06-30 13F KalVista Pharmaceuticals Equity 483497103 3,016 -14,997 -83.26 36 -83.57 0.0000
2024-05-01 2024-03-31 13F KalVista Pharmaceuticals Equity 483497103 18,013 8,750 94.46 214 88.50 0.0002
2024-02-14 2023-12-31 13F/A-2 KalVista Pharmaceuticals Equity 483497103 9,263 5,573 151.03 113 222.86 0.0001
2024-02-07 2023-12-31 13F/A-1 KalVista Pharmaceuticals Equity 483497103 9,263 5,573 113 0.0000
2024-02-07 2023-12-31 13F KalVista Pharmaceuticals Equity 483497103 9,263 113
2023-11-14 2023-09-30 13F KalVista Pharmaceuticals Equity 483497103 3,690 -9,112 -71.18 36 -69.57 0.0000
2023-08-09 2023-06-30 13F KalVista Pharmaceuticals Equity 483497103 12,802 885 7.43 115 23.66 0.0001
2023-05-12 2023-03-31 13F KALVISTA PHARMACEUTICALS EQUITY 483497103 11,917 5,808 95.07 94 126.83 0.0001
2023-02-14 2022-12-31 13F KalVista Pharmaceuticals Equity 483497103 6,109 -1,134 -15.66 41 -60.95 0.0001
2022-11-16 2022-09-30 13F/A-1 KalVista Pharmaceuticals Equity 483497103 7,243 1,285 21.57 105 81.03 0.0002
2022-11-15 2022-09-30 13F KalVista Pharmaceuticals Equity 483497103 7,243 1,285 105 0.0000
2022-08-12 2022-06-30 13F KalVista Pharmaceuticals Equity 483497103 5,958 4,189 236.80 59 123.08 0.0001
2022-05-18 2022-03-31 13F/A-1 KalVista Pharmaceuticals Equity 483497103 1,769 -3,003 -62.93 26 -58.73 0.0000
2022-02-09 2021-12-31 13F KALVISTA PHARMACEUTICALS EQUITY 483497103 4,772 1,173 32.59 63 1.61 0.0001
2021-11-16 2021-09-30 13F/A-1 KALVISTA PHARMACEUTICALS EQUITY 483497103 3,599 2,831 368.62 63 244.44 0.0001
2021-11-12 2021-09-30 13F CARBYLAN THERAPEUTICS EQUITY 483497103 3,538 2,770 45 0.0000
2021-08-10 2021-06-30 13F KALVISTA PHARMACEUTICALS EQUITY 483497103 768 -7,606 -90.83 18 -91.63 0.0000
2021-05-07 2021-03-31 13F KALVISTA PHARMACEUTICALS EQUITY 483497103 8,374 5,417 183.19 215 283.93 0.0003
2021-02-10 2020-12-31 13F CARBYLAN THERAPEUTICS EQUITY 483497103 2,957 -581 -16.42 56 27.27 0.0001
2020-10-30 2020-09-30 13F CARBYLAN THERAPEUTICS EQUITY 483497103 3,538 2,390 208.19 45 238.46 0.0001
2020-08-06 2020-06-30 13F CARBYLAN THERAPEUTICS EQUITY 483497103 1,148 -3,456 -75.07 14 -62.86 0.0000
2020-05-13 2020-03-31 13F CARBYLAN THERAPEUTICS EQUITY 483497103 4,604 2,803 155.64 35 9.38 0.0001
2020-02-12 2019-12-31 13F CARBYLAN THERAPEUTICS EQUITY 483497103 1,801 327 22.18 32 88.24 0.0001
2019-11-07 2019-09-30 13F CARBYLAN THERAPEUTICS EQUITY 483497103 1,474 1,406 2,067.65 17 1,600.00 0.0000
2019-07-30 2019-06-30 13F CARBYLAN THERAPEUTICS EQUITY 483497103 68 68 2 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.